MARKET

NUVB

NUVB

Nuvation Bio Inc
NYSE
5.88
0.00
0.00%
Opening 11:51 02/18 EST
OPEN
5.80
PREV CLOSE
5.88
HIGH
6.00
LOW
5.73
VOLUME
952.52K
TURNOVER
--
52 WEEK HIGH
9.75
52 WEEK LOW
1.540
MARKET CAP
2.02B
P/E (TTM)
-9.1904
1D
5D
1M
3M
1Y
5Y
1D
Assessing Nuvation Bio (NUVB) Valuation After Safusidenib Moves Into Phase 3 Astrocytoma Trial
Simply Wall St · 19h ago
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
PR Newswire · 1d ago
Weekly Report: what happened at NUVB last week (0209-0213)?
Weekly Report · 2d ago
How Investors May Respond To Nuvation Bio (NUVB) Expanding Safusidenib Into a Phase 3 Glioma Trial
Simply Wall St · 5d ago
A Look At Nuvation Bio’s Valuation As Safusidenib SIGMA Trial Advances To Phase 3
Simply Wall St · 02/10 20:25
Forecasting The Future: 9 Analyst Projections For Nuvation Bio
Benzinga · 02/10 19:00
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones · 02/10 14:47
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Benzinga · 02/10 14:37
More
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Webull offers Nuvation Bio Inc stock information, including NYSE: NUVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVB stock methods without spending real money on the virtual paper trading platform.